Ziccum AB (publ) to carry out Proof-of-Concept feasibility study for pharma formulation company

(Stockholm July 2, 2019) Ziccum AB (publ) (“Ziccum”) is carrying out an early-stage feasibility study for an innovative pharma company.

The early-stage Proof of Concept study involves no financial exchange, but is to explore the compatibility of Ziccum’s air-drying capabilities with the company’s novel formulation. LaminarPace, Ziccum’s proprietary technology, air dries proteins, peptides and biologics at room temperature into stable, dry-form substances.

For more information about Ziccum, please contact:

Göran Conradson: CEO Ziccum AB

E-mail: conradson@ziccum.com

Mob: +46 709 61 55 99

About Ziccum

Ziccum AB (publ) develops new patented formulations of biological drugs where sensitivity to temperature differences, especially during transportation, currently limits medical and so commercial potential. The company’s patented technology, LaminarPace, develops dry powder formulations of drugs and vaccines that currently only exist in liquid form. By doing so Ziccum can increase the availability of drugs and vaccines in existing markets—and open up new ones.

The information above was provided by Ziccum AB (publ) through the above contact person, for publication on July 2, 2019.